Alitair Pharmaceuticals CEO, James Hoyes, presents the corporate overview and strategic direction during the National Investment Banking Association (NIBA) Meeting in NYC. The meeting ran February 27-28, 2017.
Mr. Hoyes focused on the proprietary ion-exchange resin formulation technology that supports the highly innovative Overdose Reduction technology and forms the basis of its non-narcotic and narcotic prescription cough medicines portfolio. The Overdose Reduction technology, called ODR, may serve as a significant product in the fight against the Opioid Crisis. ODR serves to minimize the risk of overdose due to the abuse and/or misuse of prescription medicines especially opioids and benzodiazepines. Mr. Hoyes also reviewed the portfolio of Orphan Drugs focused on the rare pulmonary disease called bronchiectasis.